Reports of Esophageal Cancer with Oral Bisphosphonate Use
To the Editor: Between the time of the initial marketing of alendronate in October 1995 through mid-May 2008, the Food and Drug Administration (FDA) received reports of 23 patients in…
Bisphosphonates and Cancer-Induced Bone Disease: Beyond Their Antiresorptive Activity
Bisphosphonates are primarily known for their ability to inhibit osteoclast-mediated bone resorption. They are an indispensable part of therapy for patients with cancers that cause osteolysis. However, there is now…
Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
PURPOSE: Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid. We studied the incidence, characteristics, and risk factors for the development of…
Folic acid can protect blood vessels!!
One of the more interesting studies recently published in the international Journal of cardiology describes how taking folic acid can help to regress inflammation in the lining of the blood…